1-9 of 9
Javid J. Moslehi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Javid J. Moslehi, Svea K. Wahlstrom, Anna Teschemaker, Rachel H. Mackey, Diana DeVincenzo, Leslie A. Carabuena, Samantha L. Thompson, Brittaney-Belle Elizabeth Gordon, Ning A. Rosenthal
Journal: Blood
Blood (2024) 144 (Supplement 1): 5109.
https://doi.org/10.1182/blood-2024-198681
Published: 2024
Journal Articles

Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets

Brittaney-Belle Elizabeth Gordon, Svea K. Wahlstrom, Anna Teschemaker, Rachel H. Mackey, Diana DeVincenzo, Leslie A. Carabuena, Samantha L. Thompson, Ning A. Rosenthal, Javid J. Moslehi
Journal: Blood
Blood (2024) 144 (Supplement 1): 5105.
https://doi.org/10.1182/blood-2024-198724
Published: 2024
Journal Articles

Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository

Jonathan Heimlich, Morgan Shannon, Sydney Olson, Alexander J Silver, Ariana Debevec, Zachary Copeland, Caitlyn Vlasschaert, Christina Snider, Ashwin Kishtagari, Donovan J Brown, Travis Spaulding, Manasa R Bhatta, Kelly Pugh, Shannon S Stockton, Jessica Ulloa, Yaomin Xu, Muhamed Baljevic, Sanjay Mohan, Javid J. Moslehi, Eiman Jahangir, Brent Ferrell, Jr., David Slosky, Alexander G. Bick, Michael R. Savona
Journal: Blood
Blood (2023) 142 (Supplement 1): 5594.
https://doi.org/10.1182/blood-2023-189808
Published: 2023
Journal Articles

Impact of Baseline Comorbidities and Treatment on Cardiovascular (CV) Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Systematic Literature Review (SLR) of Interventional Trials and a Targeted Literature Review (TLR) of Real-World Observational Studies in CLL

Yen-Chou Chen, Paulo Andre P. Palhares De Miranda, Bersabeh Sile, Grace Fox, Chinenye Chukwu, Javid J. Moslehi, Rupal O'Quinn
Journal: Blood
Blood (2023) 142 (Supplement 1): 6539.
https://doi.org/10.1182/blood-2023-174776
Published: 2023
Journal Articles

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Michael J. Mauro, MD, Vivian G. Oehler, MD, James E. Thompson, MD, James K. McCloskey, MD, Michael C. Heinrich, MD, Shaker R. Dakhil, MD, Irene DeGutis, PharmD, David Tabano, PhD, Wasiulla Khan, PhD, Javid J. Moslehi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-137613
Published: 2020
Journal Articles

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer R Brown, MD PhD, John C. Byrd, MD, Paolo Ghia, MD PhD, Jeff P Sharman, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, Deborah M. Stephens, DO, Clare Sun, MD, Wojciech Jurczak, John M. Pagel, MDPhD, Alessandra Ferrajoli, MD, Priti Patel, MD, Marshall Baek, Tamara Lezhava, Nataliya Kuptsova-Clarkson, MD, Javid J. Moslehi, MD, Richard R. Furman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–54.
https://doi.org/10.1182/blood-2020-134797
Published: 2020
Journal Articles

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Clinical Trials & Observations
Benjamin L. Lampson, Lijian Yu, Robert J. Glynn, Jacqueline C. Barrientos, Eric D. Jacobsen, Versha Banerji, Jeffrey A. Jones, Renata Walewska, Kerry J. Savage, Gregory F. Michaud, Javid J. Moslehi, Jennifer R. Brown
Journal: Blood
Blood (2017) 129 (18): 2581–2584.
https://doi.org/10.1182/blood-2016-10-742437
Published: 2017
Includes: Supplemental data
Journal Articles

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

John H. Chen, Daniel J. Lenihan, MD, Sharon E. Phillips, MSPH, Madan H. Jagasia, Stacey A. Goodman, MD MS, Adetola A. Kassim, MD MS, Shelton L. Lacy, Kevin T. McDonagh, Javid J. Moslehi, MD, Tarsheen K. Sethi, MD MS, David A. Slosky, Oluchi C. Ukaegbu, MD, Robert F. Cornell
Journal: Blood
Blood (2015) 126 (23): 5363.
https://doi.org/10.1182/blood.V126.23.5363.5363
Published: 2015
Journal Articles

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Jacob P. Laubach, MD, Jesús F San Miguel, MD, Pieter Sonneveld, MD, Ph.D, Robert Z. Orlowski, M.D., Ph.D., Philippe Moreau, MD, Laura Rosiñol, MD, Javid J Moslehi, MD, Edward A Faber, Jr., DO, MS, Peter M Voorhees, Loreta Marquez, MD, Avinash Desai, MD, Helgi van de Velde, Jennifer Elliott, Ph.D, Hongliang Shi, Ph.D, Edward Dow, MD, Nishith Jobanputra, DO, Dixie-Lee Esseltine, MD, FRCPC, Liviu Niculescu, MD, Kenneth C. Anderson, MD, Sagar Lonial, M.D., Paul G. Richardson, MD
Journal: Blood
Blood (2013) 122 (21): 3187.
https://doi.org/10.1182/blood.V122.21.3187.3187
Published: 2013